$CGTX
COGNITION THERAPEUTICS INC

2024 Q3 Form 10-Q Financial Statement

#000155837024011464 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.071M $3.101M
YoY Change -0.29% -6.6%
% of Gross Profit
Research & Development $11.39M $11.58M
YoY Change -2.37% 36.25%
% of Gross Profit
Depreciation & Amortization $27.00K $26.00K
YoY Change -10.0% 13.04%
% of Gross Profit
Operating Expenses $14.46M $14.68M
YoY Change -1.91% 24.21%
Operating Profit -$14.46M -$14.68M
YoY Change -1.91% 24.21%
Interest Expense -$3.000K -$7.000K
YoY Change 16.67%
% of Operating Profit
Other Income/Expense, Net $4.526M $7.637M
YoY Change -43.4% 7.7%
Pretax Income -$9.937M -$7.041M
YoY Change 47.21% 48.98%
Income Tax
% Of Pretax Income
Net Earnings -$9.937M -$7.041M
YoY Change 47.24% 48.98%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$0.18
Diluted Earnings Per Share -$0.25 -$0.18
COMMON SHARES
Basic Shares Outstanding 40.13M 40.06M
Diluted Shares Outstanding 40.42M 40.06M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.01M $28.53M
YoY Change -33.24% -23.28%
Cash & Equivalents $22.01M $28.53M
Short-Term Investments
Other Short-Term Assets $1.450M $1.918M
YoY Change 1.4% -2.54%
Inventory
Prepaid Expenses $1.450M $1.918M
Receivables
Other Receivables
Total Short-Term Assets $26.83M $33.55M
YoY Change -25.55% -19.26%
LONG-TERM ASSETS
Property, Plant & Equipment $207.0K $234.0K
YoY Change -26.33% -5.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $749.0K $819.0K
YoY Change -72.58% -66.0%
TOTAL ASSETS
Total Short-Term Assets $26.83M $33.55M
Total Long-Term Assets $749.0K $819.0K
Total Assets $27.58M $34.37M
YoY Change -28.87% -21.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.895M $3.034M
YoY Change -33.72% -25.27%
Accrued Expenses $9.505M $6.064M
YoY Change 121.67% 151.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.71M $10.92M
YoY Change 54.39% 37.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.71M $10.92M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $13.10M $11.36M
YoY Change 33.02% 18.65%
SHAREHOLDERS EQUITY
Retained Earnings -$167.3M -$157.4M
YoY Change 25.76% 24.61%
Common Stock $41.00K $40.00K
YoY Change 36.67% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.48M $23.01M
YoY Change
Total Liabilities & Shareholders Equity $27.58M $34.37M
YoY Change -28.87% -21.82%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$9.937M -$7.041M
YoY Change 47.24% 48.98%
Depreciation, Depletion And Amortization $27.00K $26.00K
YoY Change -10.0% 13.04%
Cash From Operating Activities -$6.851M -$5.997M
YoY Change 64.69% 62.26%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $3.000K
YoY Change -100.0% -83.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$3.000K
YoY Change -100.0% -83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 329.0K -138.0K
YoY Change -3390.0% -106.59%
NET CHANGE
Cash From Operating Activities -6.851M -5.997M
Cash From Investing Activities 0.000 -3.000K
Cash From Financing Activities 329.0K -138.0K
Net Change In Cash -6.522M -6.138M
YoY Change 54.18% 279.12%
FREE CASH FLOW
Cash From Operating Activities -$6.851M -$5.997M
Capital Expenditures $0.00 $3.000K
Free Cash Flow -$6.851M -$6.000M
YoY Change 62.35% 61.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001455365
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32165478
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40112268
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40886
dei Entity Registrant Name
EntityRegistrantName
Cognition Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4365359
dei Entity Address Address Line1
EntityAddressAddressLine1
2500 Westchester Ave.
dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
dei City Area Code
CityAreaCode
412
dei Local Phone Number
LocalPhoneNumber
481-2210
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40132961
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28533000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29922000
CY2024Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
3099000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1281000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1918000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3019000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
33550000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
34222000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
234000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
585000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
657000
CY2024Q2 us-gaap Assets
Assets
34369000
CY2023Q4 us-gaap Assets
Assets
35163000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3034000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3695000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6064000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4055000
CY2024Q2 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1453000
CY2023Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1701000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
174000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
185000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
544000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10920000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10169000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
440000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
520000
CY2024Q2 us-gaap Liabilities
Liabilities
11360000
CY2023Q4 us-gaap Liabilities
Liabilities
10689000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40112268
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32165478
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
40000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
180350000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165826000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157381000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141189000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-195000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
23009000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24474000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34369000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35163000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11577000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8497000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22130000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13927000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3101000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3320000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6650000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6863000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
14678000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11817000
us-gaap Operating Expenses
OperatingExpenses
28780000
us-gaap Operating Expenses
OperatingExpenses
20790000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14678000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11817000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28780000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20790000
CY2024Q2 cgtx Grant Income
GrantIncome
7311000
CY2023Q2 cgtx Grant Income
GrantIncome
6925000
cgtx Grant Income
GrantIncome
12223000
cgtx Grant Income
GrantIncome
10351000
CY2024Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
333000
CY2023Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
172000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
577000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-443000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-17000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-16000
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
195000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7637000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7091000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12588000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9892000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4726000
us-gaap Net Income Loss
NetIncomeLoss
-16192000
us-gaap Net Income Loss
NetIncomeLoss
-10898000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
195000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7041000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4727000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15997000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10895000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40062954
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29614822
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36899112
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29356144
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40062954
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29614822
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36899112
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29356144
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24474000
CY2024Q1 cgtx Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
-106000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1171000
CY2024Q1 cgtx Reclassifications Adjustment Of Foreign Currency Translation Included In Net Loss For Liquidation Of Subsidiary
ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary
195000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9151000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
28860000
CY2024Q2 cgtx Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
-22000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1147000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
23009000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
40249000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1187000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6172000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
35783000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1025000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4726000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
34386000
us-gaap Net Income Loss
NetIncomeLoss
-16192000
us-gaap Net Income Loss
NetIncomeLoss
-10898000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000
us-gaap Share Based Compensation
ShareBasedCompensation
2318000
us-gaap Share Based Compensation
ShareBasedCompensation
2212000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
72000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
77000
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
195000
cgtx Issuance Of Common Stock As Commitment Shares For Equity Line Financing
IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing
318000
cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
1818000
cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-1279000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1101000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-752000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1348000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1165000
cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
-248000
cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
-1280000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-70000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-70000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13241000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6401000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
128000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
359000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
417000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11855000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2085000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1389000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4372000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29922000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41562000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28533000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37190000
us-gaap Net Income Loss
NetIncomeLoss
-16192000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25788000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28533000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29922000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157381000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q2 cgtx Allowance For Credit Loss Grants Receivable Current
AllowanceForCreditLossGrantsReceivableCurrent
0
CY2024Q2 cgtx Grant Income
GrantIncome
7311000
cgtx Grant Income
GrantIncome
12223000
CY2023Q2 cgtx Grant Income
GrantIncome
6925000
cgtx Grant Income
GrantIncome
10351000
CY2024Q2 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1453000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1701000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
28295000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
29391000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1092000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1165000
CY2024Q2 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4759000
CY2023Q4 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2520000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
213000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
370000
CY2024Q2 cgtx Operating Lease Assets
OperatingLeaseAssets
585000
CY2023Q4 cgtx Operating Lease Assets
OperatingLeaseAssets
657000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
585000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
657000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
174000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
440000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
520000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
624000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
694000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
55000
us-gaap Operating Lease Expense
OperatingLeaseExpense
109000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
54000
us-gaap Operating Lease Expense
OperatingLeaseExpense
108000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
112000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
226000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
158000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
91000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
92000
CY2024Q2 cgtx Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
39000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
718000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
94000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
624000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
us-gaap Operating Lease Payments
OperatingLeasePayments
112000
us-gaap Operating Lease Payments
OperatingLeasePayments
99000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9178
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9229
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9268
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0423
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0445
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0346
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0421
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4213405
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.73
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1579000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
247500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73350
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4225
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1250
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.66
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4382080
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.65
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1121000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3492857
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.04
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1095000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.56
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.61
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
42500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
247500
CY2024Q2 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
65000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
385000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
163549
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
576269
CY2023Q2 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
257000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
925000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73350
CY2024Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73350
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
46000
CY2024Q2 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
46000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1147000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1025000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2318000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2212000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3957000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M17D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5552328
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4688771
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011464-index-headers.html Edgar Link pending
0001558370-24-011464-index.html Edgar Link pending
0001558370-24-011464.txt Edgar Link pending
0001558370-24-011464-xbrl.zip Edgar Link pending
cgtx-20240630.xsd Edgar Link pending
cgtx-20240630x10q.htm Edgar Link pending
cgtx-20240630xex31d1.htm Edgar Link pending
cgtx-20240630xex31d2.htm Edgar Link pending
cgtx-20240630xex32d1.htm Edgar Link pending
cgtx-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
cgtx-20240630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cgtx-20240630x10q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cgtx-20240630_def.xml Edgar Link unprocessable
cgtx-20240630_pre.xml Edgar Link unprocessable
cgtx-20240630_lab.xml Edgar Link unprocessable